Emergent BioSolutions | EBS - Ordinary Share Capital


Emergent BioSolutions reported $100K in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 168.03M 489K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amarin USD 20.81M 13K Dec/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Emergent BioSolutions USD 100K 0 Jun/2023
Exelixis USD 244.68M 4.21M Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
Lonza CHF 68.64M 0 Dec/2025
Merck USD 2.47B 1.05M Jun/2026
Moderna USD 391M 2M Sep/2025
Myriad Genetics USD 93.5M 400K Dec/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Pacira USD 39.9M 75K Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
United Therapeutics USD 42.38M 295K Sep/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024